Exact Sciences Corp
EXAS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$73.00 | Zmpl | Jbwnzbkp |
Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins
Exact Science's fourth-quarter results and 2024 guidance were in line with our expectations. The midpoint of the revenue guidance ranges is $2.83 billion for total revenue, $2.165 billion for screening, and $665 million for Precision Oncology, which are year-on-year growth rates of 13%, 16%, and 6%, respectively. We maintain our fair value estimate of $78 per share. The shares are trading at a 14% discount to this, which we view as slightly undervalued.